Title:
Hospital Infection Therapeutics Market (Drug Type: Antibacterial, Antiviral and Antifungal Drugs; Infection Type: Hospital-Acquired Pneumonia, Urinary Tract Infections, Gastrointestinal Disorders, Bloodstream Infections, Surgical Site Infections and Other Hospital Infections) - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020.
This report on hospital infection therapeutics, studies the current as well as
future prospects of the market globally. Hospital infections are also referred
to as healthcare-associated infections (HCAIs), or nosocomial infections or
hospital-acquired infection (HAIs). HAIs can be defined as those infections
that occur in patients when they are admitted to a hospital or any other
health-care facility with which they were not suffering from at the time of
their admission. A Hospital infection also includes those infections that are
acquired in the hospital but appear after the discharge of the patient, as
well as the occupational infections among hospital staff. Several
antimicrobial drugs have proven their effectiveness in treating a range of
hospital infections that are globally prevalent at present. This report
comprises of an elaborate executive summary, which includes a market snapshot
that provides overall information of various segments and sub-segments that
are contained in the report. It also provides an overall information and data
analysis of the global hospital infection therapeutics market with respect to
market segments based on type of drugs used, major hospital infections and
geographic regions.
The market for hospital infection therapeutics is segmented into three major
therapeutic drug types, namely, antibacterial, antiviral and antifungal drugs.
The hospital infection therapeutics market is also segmented on the basis of
major hospital infection types, into six major categories, namely, hospital
acquired pneumonia, urinary tract infections, gastrointestinal disorders,
bloodstream infections, surgical site infections and other hospital
infections. The market has been extensively analyzed on the basis of the
usefulness, effectiveness and sales revenue of major drug types as well as
geographic prevalence of major types of hospital infections. The market size
and forecast in terms of USD million for each drug as well as major infection
types has been provided for the period 2012 to 2020, considering 2013 as the
base year. The report also provides the compounded annual growth rate (CAGR %)
for each market segment for the forecast period 2014 to 2020.
Geographically, the hospital infection therapeutics market has been
categorized into four regions namely, North America, Europe, Asia Pacific, and
Rest of the World (ROW). The market size and forecast for each of these
regions has been provided for the period 2012 to 2020 along with the CAGR for
the forecast period 2014 to 2020. The report also comprises a section on
pipeline analysis for this market that includes sales forecast for various
drugs currently under phase III clinical trials and expected to be launched
during the forecast period. Major pipeline drugs that have been included in
the report are Amikacin Inhale, CAZ AVI, Ceftolozane/Tazobactam, Dalvance,
Delafloxacin, Eravacycline, MK-3415A, Oritavancin, Plazomicin, Surotomycin and
Tedizolid. The research study also incorporates the competitive scenario in
these regions. A detailed qualitative analysis of the factors responsible for
driving and restraining the growth of this market and future opportunities has
been provided in the market overview section. This section of the report also
deals with market attractiveness analysis, Porter's five forces analysis and
competitive analysis of the key players in 2013 in the global hospital
infection therapeutics market.
A list of recommendations has been provided for new entrants as well as
existing market players to help them establish a strong presence in the market
and increase their share. The report also profiles major players of the
hospital infection therapeutics market on the basis of various attributes such
as company overview, financial overview, business strategies, product
portfolio and recent developments. Some of the major players profiled in this
report include Actavis plc, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb
Company, Cubist Pharmaceuticals, Inc., GlaxoSmithKline plc, Johnson & Johnson
Services, Inc., Merck & Co., Inc., Pfizer, Inc., and Sanofi.
The global hospital infection therapeutics market is segmented as follows:
Hospital Infection Therapeutics Market, by Drug Type
- Antibacterial Drugs
- Antiviral Drugs
- Antifungal Drugs
Hospital Infection Therapeutics Market, by Major Infections
- Hospital-Acquired Pneumonia
- Surgical Site Infections
- Urinary Tract Infections
- Gastrointestinal Disorders
- Bloodstream Infections
- Other Hospital Infections
Hospital Infection Therapeutics Market, by Geography
- North America
- Europe
- Asia Pacific
- Rest of the World (RoW)
Table of Contents
Chapter 1 - Introduction
- 1.1. Report Description
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Assumptions
Chapter 2 - Executive Summary
- 2.1. Market Snapshot: Global Hospital Infection Therapeutics Market
- 2.2. Comparative Analysis: Global Hospital Infection Therapeutics Market,
by Geography, 2013 & 2020 (Value %)
Chapter 3 - Hospital Infection Therapeutics Market Overview
- 3.1. Introduction
- 3.2. Event Impact Analysis
- 3.3. Market Drivers
- 3.3.1. High Prevalence of Various Hospital Infections Driving the Demand
for Anti-infective Drugs
- 3.3.2. High Susceptibility of Neonatal Population in a Healthcare
Setting Giving Rise to Different Hospital Infections
- 3.3.3. Lack of Skilled Nursing Staff in Developing and Underdeveloped
Economies is Increasing the Prevalence of HAIs
- 3.4. Market Restraints
- 3.4.1. Increasing Hospital Surveillance and Infection Control Programs
in Developed Countries Leading to a Decline in Number of Hospital Infections
- 3.4.2. Increasing Number of Multi-drug resistant Bacterial Strains
making Presently Available Antibacterial Drugs Obsolete
- 3.5. Market Opportunities
- 3.5.1. High Number of Pipeline Drug Molecules for Specific Treatment of
HAIs
- 3.5.2. Increasing Incidences of Hospital Infections and High Unmet Needs
in Low to Medium Income Countries of the World
- 3.6. Value Chain Analysis
- 3.7. Porter's Five Forces Analysis: Global Hospital Infection Therapeutics
Market
- 3.7.1. Bargaining Power of Suppliers
- 3.7.2. Bargaining Power of Buyers
- 3.7.3. Threat of Substitutes
- 3.7.4. Threat of New Entrants
- 3.7.5. Competitive Rivalry
- 3.8. Market Attractiveness Analysis: Global Hospital Infection
Therapeutics Market, by Geography
- 3.9. Competitive Landscape
- 3.9.1. Market Share Analysis by Key Players: Hospital Infection
Therapeutics Market, 2013 (Value %)
Chapter 4 - Hospital Infection Therapeutics Market, by Drug Type
- 4.1. Overview
- 4.1.1. Global Hospital Infection Therapeutics Market Revenue, by Drug
Type, 2012 - 2020 (USD Million)
- 4.1.2. Comparative Analysis: Global Hospital Infection Therapeutics
Market Revenue, by Drug Type, 2013 & 2020 (Value %)
- 4.2. Antibacterial Drugs
- 4.2.1. Global Antibacterial Drugs in HIT Market Revenue, 2012 - 2020 (USD
Million)
- 4.3. Antiviral Drugs
- 4.3.1. Global Antiviral Drugs in HIT Market Revenue, 2012 - 2020 (USD
Million)
- 4.4. Antifungal Drugs
- 4.4.1. Global Antifungal Drugs in HIT Market Revenue, 2012 - 2020 (USD
Million)
- 4.5. Pipeline Analysis: Market Forecast
- 4.5.1. Amikacin Inhale
- 4.5.1.1. Global Amikacin Inhale Market Revenue (Expected), 2016 - 2020
(USD Million)
- 4.5.2. CAZ AVI (Ceftazidime/avibactum)
- 4.5.2.1. Global CAZ AVI Market Revenue (Expected), 2015 - 2020 (USD
Million)
- 4.5.3. Ceftolozane/Tazobactam
- 4.5.3.1. Global Ceftolozane/tazobactam Market Revenue (Expected), 2015
- 2020 (USD Million)
- 4.5.4. Dalvance (dalbavancin)
- 4.5.4.1. Global Dalvance (dalbavancin) Market Revenue (Expected), 2016
- 2020 (USD Million)
- 4.5.5. Delafloxacin (RX-3341)
- 4.5.5.1. Global Delafloxacin Market Revenue (Expected), 2015 - 2020
(USD Million)
- 4.5.6. Eravacycline (TP-434)
- 4.5.6.1. Global Eravacycline Market Revenue (Expected), 2017 - 2020
(USD Million)
- 4.5.7. MK-3415A
- 4.5.7.1. Global MK-3415A Market Revenue (Expected), 2016 - 2020 (USD
Million)
- 4.5.8. Oritavancin
- 4.5.8.1. Global Oritavancin Market Revenue (Expected), 2017 - 2020 (USD
Million)
- 4.5.9. Plazomicin
- 4.5.9.1. Global Plazomicin Market Revenue (Expected), 2017 - 2020 (USD
Million)
- 4.5.10. Surotomycin (CB-315)
- 4.5.10.1. Global Surotomycin Market Revenue (Expected), 2017 - 2020
(USD Million)
- 4.5.11. Tedizolid (TR-701)
- 4.5.11.1. Global Tedizolid Market Revenue (Expected), 2015 - 2020 (USD
Million)
Chapter 5 - Hospital Infection Therapeutics Market, by Major Infections
- 5.1. Overview
- 5.1.1. Global Hospital Infection Therapeutics Market Revenue, by Major
Infections, 2012 - 2020 (USD Million)
- 5.1.2. Comparative Analysis: Global Hospital Infection Therapeutics
Market Revenue, by Major Infections, 2013 & 2020 (Value %)
- 5.2. Hospital-Acquired Pneumonia (HAP)
- 5.2.1. Global HAP Therapeutics Market Revenue, 2012 - 2020 (USD Million)
- 5.3. Surgical Site Infections (SSIs)
- 5.3.1. Global Surgical Site Infection Therapeutics Market Revenue, 2012 -
2020 (USD Million)
- 5.4. Urinary Tract Infections (UTIs)
- 5.4.1. Global UTI Therapeutics Market Revenue, 2012 - 2020 (USD Million)
- 5.5. Gastrointestinal Disorders
- 5.5.1. Global Gastrointestinal Disorders Therapeutics Market Revenue,
2012 - 2020 (USD Million)
- 5.6. Bloodstream Infections
- 5.6.1. Global Bloodstream Infection Therapeutics Market Revenue, 2012 -
2020 (USD Million)
- 5.7. Other Hospital Infections
- 5.7.1. Global Other Hospital Infection Therapeutics Market Revenue, 2012
- 2020 (USD Million)
Chapter 6 - Hospital infection therapeutics Market, by Geography
- 6.1. Overview
- 6.1.1. Global Hospital infection therapeutics Market Revenue, by
Geography, 2012 - 2020 (USD Million)
- 6.2. North America
- 6.2.1. North America Hospital infection therapeutics Market Revenue, 2012
- 2020 (USD Million)
- 6.3. Europe
- 6.3.1. Europe Hospital infection therapeutics Market Revenue, 2012 -
2020 (USD Million)
- 6.4. Asia Pacific
- 6.4.1. Asia Pacific Hospital infection therapeutics Market Revenue, 2012
- 2020 (USD Million)
- 6.5. Rest of the World (RoW)
- 6.5.1. RoW Hospital infection therapeutics Market Revenue, 2012 - 2020
(USD Million)
Chapter 7 - Recommendations
Chapter 8. -Company Profiles
- 8.1. Actavis plc
- 8.1.1. Company Overview
- 8.1.2. Financial Overview
- 8.1.3. Product Portfolio
- 8.1.4. Business Strategies
- 8.1.5. Recent Developments
- 8.2. AstraZeneca plc
- 8.2.1. Company Overview
- 8.2.2. Financial Overview
- 8.2.3. Product Portfolio
- 8.2.4. Business Strategies
- 8.2.5. Recent Developments
- 8.3. Bayer AG
- 8.3.1. Company Overview
- 8.3.2. Financial Overview
- 8.3.3. Product Portfolio
- 8.3.4. Business Strategies
- 8.3.5. Recent Developments
- 8.4. Bristol-Myers Squibb Company
- 8.4.1. Company Overview
- 8.4.2. Financial Overview
- 8.4.3. Product Portfolio
- 8.4.4. Business Strategies
- 8.4.5. Recent Developments
- 8.5. Cubist Pharmaceuticals, Inc.
- 8.5.1. Company Overview
- 8.5.2. Financial Overview
- 8.5.3. Product Portfolio
- 8.5.4. Business Strategies
- 8.5.5. Recent Developments
- 8.6. GlaxoSmithKline plc
- 8.6.1. Company Overview
- 8.6.2. Financial Overview
- 8.6.3. Product Portfolio
- 8.6.4. Business Strategies
- 8.6.5. Recent Developments
- 8.7. Johnson & Johnson Services, Inc.
- 8.7.1. Company Overview
- 8.7.2. Financial Overview
- 8.7.3. Product Portfolio
- 8.7.4. Business Strategies
- 8.7.5. Recent Developments
- 8.8. Merck & Co., Inc.
- 8.8.1. Company Overview
- 8.8.2. Financial Overview
- 8.8.3. Product Portfolio
- 8.8.4. Business Strategies
- 8.8.5. Recent Developments
- 8.9. Pfizer, Inc.
- 8.9.1. Company Overview
- 8.9.2. Financial Overview
- 8.9.3. Product Portfolio
- 8.9.4. Business Strategies
- 8.9.5. Recent Developments
- 8.10. Sanofi
- 8.10.1. Company Overview
- 8.10.2. Financial Overview
- 8.10.3. Product Portfolio
- 8.10.4. Business Strategies
- 8.10.5. Recent Developments
List of Figures
- FIG. 1: Hospital Infection Therapeutics: Market Segmentation
- FIG. 2: Global Hospital Infection Therapeutics Market, by Drug Type, 2013
(USD Million)
- FIG. 3: Global Hospital Infection Therapeutics Market, by Major
Infections, 2013 (USD Million)
- FIG. 4: Comparative Analysis: Global Hospital Infection Therapeutics
Market, by Geography, 2013 & 2020 (Value %)
- FIG. 5: Global Hospital Infection Therapeutics Market: Event Impact
Analysis
- FIG. 6: Global Hospital Infection Therapeutics Market, Value Chain Analysis
- FIG. 7: Porter's Five Forces Analysis: Global Hospital Infection
Therapeutics Market, 2012 - 2020
- FIG. 8: Market Attractiveness Analysis: Global Hospital Infection
Therapeutics Market, by Geography (2013)
- FIG. 9: Market Share Analysis: Hospital Infection Therapeutics Market,
2013 (Value %)
- FIG. 10: Comparative Analysis: Global Hospital Infection Therapeutics
Market Revenue, by Drug Type, 2013 & 2020 (Value %)
- FIG. 11: Global Antibacterial Drugs in HIT Market Revenue, 2012 - 2020
(USD Million)
- FIG. 12: Global Antiviral Drugs in HIT Market Revenue, 2012 - 2020 (USD
Million)
- FIG. 13: Global Antifungal Drugs in HIT Market Revenue, 2012 - 2020 (USD
Million)
- FIG. 14: Global Amikacin Inhale Market Revenue (Expected), 2016 - 2020
(USD Million)
- FIG. 15: Global CAZ AVI Market Revenue (Expected), 2015 - 2020 (USD
Million)
- FIG. 16: Global Ceftolozane/tazobactam Market Revenue (Expected), 2015 -
2020 (USD Million)
- FIG. 17: Global Dalvance (Dalbavancin) Market Revenue (Expected), 2016 -
2020 (USD Million)
- FIG. 18: Global Delafloxacin Market Revenue (Expected), 2015 - 2020 (USD
Million)
- FIG. 19: Global Eravacycline Market Revenue (Expected), 2017 - 2020 (USD
Million)
- FIG. 20: Global MK-3415A Market Revenue (Expected), 2016 - 2020 (USD
Million)
- FIG. 21: Global Oritavancin Market Revenue (Expected), 2017 - 2020 (USD
Million)
- FIG. 22: Global Plazomicin Market Revenue (Expected), 2017 - 2020 (USD
Million)
- FIG. 23: Global Surotomycin Market Revenue (Expected), 2017 - 2020 (USD
Million)
- FIG. 24: Global Tedizolid Market Revenue (Expected), 2015 - 2020 (USD
Million)
- FIG. 25: Comparative Analysis: Global Hospital Infection Therapeutics
Market Revenue, by Major Infections, 2013 & 2020 (Value %)
- FIG. 26: Global HAP Therapeutics Market Revenue, 2012 - 2020 (USD Million)
- FIG. 27: Global Surgical Site Infection Therapeutics Market Revenue, 2012
- 2020 (USD Million)
- FIG. 28: Global UTI Therapeutics Market Revenue, 2012 - 2020 (USD Million)
- FIG. 29: Global Gastrointestinal Disorders Therapeutics Market Revenue,
2012 - 2020 (USD Million)
- FIG. 30: Global Bloodstream Infection Therapeutics Market Revenue, 2012 -
2020 (USD Million)
- FIG. 31: Global Other Hospital Infection Therapeutics Market Revenue, 2012
- 2020 (USD Million)
- FIG. 32: North America Hospital infection therapeutics Market Revenue,
2012 - 2020 (USD Million)
- FIG. 33: Europe Hospital infection therapeutics Market Revenue, 2012 -
2020 (USD Million)
- FIG. 34: Asia Pacific Hospital infection therapeutics Market Revenue, 2012
- 2020 (USD Million)
- FIG. 35: RoW Hospital infection therapeutics Market Revenue, 2012 - 2020
(USD Million)
- FIG. 36: Actavis plc: Annual Revenue, 2011 - 2013 (USD Million)
- FIG. 37: AstraZeneca plc: Annual Revenue, 2011 - 2013 (USD Million)
- FIG. 38: Bayer AG: Annual Revenue, 2011 - 2013 (USD Million)
- FIG. 39: Bristol-Myers Squibb Company: Annual Revenue, 2011 - 2013 (USD
Million)
- FIG. 40: Cubist Pharmaceuticals, Inc.: Annual Revenue, 2011 - 2013 (USD
Million)
- FIG. 41: GlaxoSmithKline plc: Annual Revenue, 2011 - 2013 (USD Million)
- FIG. 42: Johnson & Johnson: Annual Revenue, 2011 - 2013 (USD Million)
- FIG. 43: Merck & Co., Inc.: Annual Revenue, 2011 - 2013 (USD Million)
- FIG. 44: Pfizer, Inc.: Annual Revenue, 2011 - 2013 (USD Million)
- FIG. 45: Sanofi: Annual Revenue, 2011 - 2013 (USD Million)
List of Tables
- TABLE 1: Market Snapshot: Global Hospital Infection Therapeutics Market
- TABLE 2: Global Hospital Infection Therapeutics Market Revenue, by Drug
Type, 2012 - 2020 (USD Million)
- TABLE 3: Comparison of Major Resistant Bacterial Strains Prevalence
Against Major Therapeutic Drug Classes, in Respective Years (2008 & 2013)
- TABLE 4: Global Hospital Infection Therapeutics Market Revenue, by Major
Infections, 2012 - 2020 (USD Million)
- TABLE 5: Global Hospital infection therapeutics Market Revenue, by
Geography, 2012 - 2020 (USD Million)
